-+ 0.00%
-+ 0.00%
-+ 0.00%

SciSparc subsidiary NeuroThera Labs enrolls 26 children in SCI-210 autism trial

PUBT·08/31/2026 20:03:19
Listen to the news
SciSparc subsidiary NeuroThera Labs enrolls 26 children in SCI-210 autism trial
  • SciSparc’s subsidiary NeuroThera Labs accelerated enrollment in its SCI-210 pediatric autism trial, reaching 26 participants toward a 60-child target.
  • Trial at Soroka Medical Center tests a CBD plus CannAmide formulation versus CBD monotherapy in a double-blind, randomized, placebo-controlled design.
  • Participants ages 5-18 receive 20 weeks of treatment; key readouts track behavioral change, clinician-rated improvement, safety, dose optimization.
  • NeuroThera plans to pursue commercialization in Israel first, subject to successful development and regulatory clearances.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311603PRIMZONEFULLFEED9818772) on August 31, 2026, and is solely responsible for the information contained therein.